Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04010968
Title Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia (ERADIC)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors French Innovative Leukemia Organisation
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib + Venetoclax

Cyclophosphamide + Fludarabine + Rituximab

Age Groups: adult | senior
Covered Countries FRA

Additional content available in CKB BOOST